The chief executive and a lead scientist stepped down weeks after a federal grand jury filed fraud charges against a research ...
The FDA approved donanemab, which will be sold under the brand name Kisunla. The new drug helps slow decline in Alzheimer's patients with mild cognitive impairment.
Alzheimer’s has no cure and can’t be reversed, but the FDA-approved drug can slow cognitive decline. Eli Lilly reported that ...
The US Food and Drug Administration approved Donanemab, also called Kisunla. Tuesday's decision put the monoclonal antibody ...
FDA designation enables expedited clinical development and regulatory review timelines for Lomecel-B™ –– Second designation received for ...
It's not a cure-- but it is a step in the right direction.This month-- a new medication for alzheimer's, called 'kinsul'a, ...
The case centers on a Form 483, a warning letter the FDA issues if pharmaceutical companies fail ... the timing and ultimate ...
Novo Holdings led Asceneuron’s $100 million Series C financing. The Merck Serono spinout’s lead program is an oral small molecule designed to prevent aggregation of tau protein in neurodegenerative ...
A Massachusetts company that makes diagnostic imaging agents and products is expanding its Alzheimer’s disease pipeline with ...
Asceneuron, which develops small molecules targeting tau protein aggregation, plans to use the funds to advance its Alzheimer ...
MALVERN, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical ...